OneSource Specialty Pharma Unaudited Financial Results for Quarter Ended September 30, 2025

OneSource Specialty Pharma Limited announced its unaudited consolidated financial results for the quarter and six months ended September 30, 2025. The company reported a total income of ₹3,787.99 million for the quarter. While the company witnessed a profit before tax of ₹57.41 million this quarter, the profit after tax stood at ₹104.85 million. Earnings per share for continuing operations was reported as ₹0.92.

Financial Performance Overview

OneSource Specialty Pharma Limited has released its unaudited financial results for Q2 2025, showing a mixed financial landscape. Here are the key highlights from the announcement:

Key Financial Figures

  • Total Income: Total income reached ₹3,787.99 million for the quarter.
  • Profit Before Tax: The company saw a profit before tax of ₹57.41 million.
  • Profit After Tax: Profit after tax stood at ₹104.85 million.
  • Earnings Per Share: Earnings per share for continuing operations was reported as ₹0.92.

Expenses

The expenses for the quarter included:

  • Cost of materials consumed: ₹677.25 million.
  • Employee benefits expenses: ₹628.21 million.
  • Finance costs: ₹339.63 million.
  • Depreciation and amortisation expenses: ₹698.27 million.
  • Other expenses: ₹929.57 million.

Segment Performance

The company’s revenue from the CDMO (Contract Development and Manufacturing Organization) segment reached ₹3,757.63 million. The segment reported a profit before tax of ₹57.41 million for the quarter.

Other Comprehensive Income

Other comprehensive income includes:

  • Exchange differences in translating the financial statements of foreign operations: ₹58.18 million.

Composite Scheme of Arrangement

During the current quarter, the Company has entered into Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) amongst Steriscience Specialties Private Limited and other entities. The Company is in the process of obtaining relevant regulatory approvals.

Claims not Acknowledged

Biolexis Pte Limited, a subsidiary of the Company, has received a claim from Prestige Biopharma Limited of USD 136.32 million (₹12,114.89 million). The same has not been acknowledged as debt in the books of Group.

Source: BSE

InvestyWise News
InvestyWise News
Covers market-moving news with speed and precision, delivering sharp insights to help readers stay ahead in the fast-paced world of stocks.

Latest articles

Related articles

Leave a reply

Please enter your comment!
Please enter your name here
Captcha verification failed!
CAPTCHA user score failed. Please contact us!